IXC

0.00%

6.6¢ invex therapeutics ltd

Very well put

First 92 Last

Share
Profile

Follow
SSilverstein

795 Posts.

45

28/06/23

16:27

Post #: 68517446
Share

Originally posted by arkangel256: ↑

I am rarely critical of the BoD who I still feel have been world class up to this point. But Tom Duthy should have organised a teleconference call to allow investors to ask questions, given the material change to the company's strategy. The lack of teleconference, even next week, could be interpreted as the BoD shying away from being accountable to their shareholders and lacks the spirit by which they've previously conducted themselves.

There is now a live prospect that the TAM will be destroyed by the burgeoning GLP-1 agonist treatment for obesity, in which case the business case for IIH may not be lucrative. Whilst unlikely, the company needs to rapidly decide whether its worth stopping the IIH clinical program and return capital to shareholders. Drug development takes a decade, so I can't see them move a secondary indication e.g. TBI to their lead indication.

If I was a director, I would be deciding the fastest way to salvage shareholder value, in the shortest time span possible given the rapidly changing nature of the GLP-1 market. They need to commit as soon as possible to running the IIH trial(pushing well into the 3rd quarter is too long) or if the risk is too great, to stop the program and return the funds to shareholders. There is no assurity that the EMA will accept the proposed protocol changes e.g. LP for the last 6 months.

If they proceed with the IIH EVOLVE trial with EMA approval, they have to proceed with running one or two proof of study trials in TBI and Stroke whilst waiting for the IIH trial to recruit. This is imperative in case IIH EVOLVE fails or the TAM gets eroded due to GLP-1 market, then at least they have proven ICP reduction to justify valuation on the other indications.

I am still holding today, but today was a deeply disappointing day and has been deepened by a sense of abandonment from the BoD.

Expand

Very well put

IXC Price at posting: 22.0¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Bitcoin investors need to know the risks

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

There are more pages in this discussion • 133 more messages in this thread...

First 92 Last

Add IXC (ASX) to my watchlist

(20min delay)
Last 6.6¢		Change 0.000(0.00%)		Mkt cap ! $4.960M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	100000	6.2¢

Sellers (Offers)

Price($)	Vol.	No.
6.8¢	10000	1

View Market Depth

No.	Vol.	Price($)
1	100000	0.062
1	15500	0.061
1	150000	0.060
1	100000	0.052
1	60001	0.041

Price($)	Vol.	No.
0.068	10000	1
0.069	16500	1
0.070	40000	1
0.076	888	1
0.083	4000	1

Last trade - 16.12pm 12/07/2024 (20 minute delay)

IXC (ASX) Chart

Day chart unavailable

Very well put

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Immutep reports strong response rate from immunotherapies treating carcinomas

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Nimy to raise $1.21M to explore 'newsy' WA targets

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Bitcoin investors need to know the risks

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Very well put

Top Stories

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Immutep reports strong response rate from immunotherapies treating carcinomas

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Nimy to raise $1.21M to explore 'newsy' WA targets

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Bitcoin investors need to know the risks

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News